281 related articles for article (PubMed ID: 28796802)
21. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
22. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer.
Earl J; Garcia-Nieto S; Martinez-Avila JC; Montans J; Sanjuanbenito A; Rodríguez-Garrote M; Lisa E; Mendía E; Lobo E; Malats N; Carrato A; Guillen-Ponce C
BMC Cancer; 2015 Oct; 15():797. PubMed ID: 26498594
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis.
Kwak MS; Cha JM; Yoon JY; Jeon JW; Shin HP; Chang HJ; Kim HK; Joo KR; Lee JI
Medicine (Baltimore); 2017 Sep; 96(35):e7882. PubMed ID: 28858102
[TBL] [Abstract][Full Text] [Related]
24. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
Pan W; Yang Y; Zhu H; Zhang Y; Zhou R; Sun X
Oncotarget; 2016 Feb; 7(7):8373-88. PubMed ID: 26840022
[TBL] [Abstract][Full Text] [Related]
25. Optimization of circulating cell-free DNA recovery for KRAS mutation and HPV detection in plasma.
Mazurek AM; Fiszer-Kierzkowska A; Rutkowski T; Składowski K; Pierzyna M; Scieglińska D; Woźniak G; Głowacki G; Kawczyński R; Małusecka E
Cancer Biomark; 2013; 13(5):385-94. PubMed ID: 24440979
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of circulating cell-free DNA in patients with pancreatic cancer: A systemic review and meta-analysis.
Chen L; Zhang Y; Cheng Y; Zhang D; Zhu S; Ma X
Gene; 2018 Dec; 679():328-334. PubMed ID: 30227250
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.
Won DD; Lee JI; Lee IK; Oh ST; Jung ES; Lee SH
BMC Cancer; 2017 Jun; 17(1):403. PubMed ID: 28583095
[TBL] [Abstract][Full Text] [Related]
28. Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non-Small Cell Lung Cancer Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Zer A; Ding K; Lee SM; Goss GD; Seymour L; Ellis PM; Hackshaw A; Bradbury PA; Han L; O'Callaghan CJ; Tsao MS; Shepherd FA
J Thorac Oncol; 2016 Mar; 11(3):312-23. PubMed ID: 26749487
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.
Brudvik KW; Kopetz SE; Li L; Conrad C; Aloia TA; Vauthey JN
Br J Surg; 2015 Sep; 102(10):1175-83. PubMed ID: 26206254
[TBL] [Abstract][Full Text] [Related]
30. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
Han JY; Choi JJ; Kim JY; Han YL; Lee GK
BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
[TBL] [Abstract][Full Text] [Related]
31. Meta-Analysis of Circulating Cell-Free DNA's Role in the Prognosis of Pancreatic Cancer.
Milin-Lazovic J; Madzarevic P; Rajovic N; Djordjevic V; Milic N; Pavlovic S; Veljkovic N; Milic NM; Radenkovic D
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298594
[TBL] [Abstract][Full Text] [Related]
32. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Implications of Multiplex Detection of
Kim MK; Woo SM; Park B; Yoon KA; Kim YH; Joo J; Lee WJ; Han SS; Park SJ; Kong SY
Clin Chem; 2018 Apr; 64(4):726-734. PubMed ID: 29352043
[TBL] [Abstract][Full Text] [Related]
35. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
36. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
37. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.
Berger AW; Schwerdel D; Welz H; Marienfeld R; Schmidt SA; Kleger A; Ettrich TJ; Seufferlein T
PLoS One; 2017; 12(3):e0174308. PubMed ID: 28328955
[TBL] [Abstract][Full Text] [Related]
38. Integrating
Ntavatzikos A; Spathis A; Patapis P; Machairas N; Peros G; Konstantoudakis S; Leventakou D; Panayiotides IG; Karakitsos P; Koumarianou A
World J Gastroenterol; 2017 Aug; 23(32):5913-5924. PubMed ID: 28932083
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.
Tao LY; Zhang LF; Xiu DR; Yuan CH; Ma ZL; Jiang B
World J Surg Oncol; 2016 May; 14():146. PubMed ID: 27183870
[TBL] [Abstract][Full Text] [Related]
40. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
Spindler KL; Appelt AL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
Int J Cancer; 2014 Dec; 135(12):2984-91. PubMed ID: 24798213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]